MARY15 is a pyridinylpiperazine-based derivative of MARY1. MARY15 activates uncoupled mitochondrial respiration and upregulates p-AKT (S473) phosphorylation in renal proximal tubule cells [1].
In Vitro, MARY15 (30 nM; 24 h) activates uncoupled mitochondrial respiration in renal proximal tubule cells, as measured by FCCP-OCR[1]. MARY15 (30 nM; 1 h) upregulates p-AKT (S473) phosphorylation in renal proximal tubule cells[1].
References:
[1]. Rick Schnellmann, et al. Mary1 and derivatives thereof for the treatment of mitochondrial dysfunction, vascular injury, kidney diseases, and organ aging, WO, WO2025240390A1, 2025-11-20.
In Vitro, MARY15 (30 nM; 24 h) activates uncoupled mitochondrial respiration in renal proximal tubule cells, as measured by FCCP-OCR[1]. MARY15 (30 nM; 1 h) upregulates p-AKT (S473) phosphorylation in renal proximal tubule cells[1].
References:
[1]. Rick Schnellmann, et al. Mary1 and derivatives thereof for the treatment of mitochondrial dysfunction, vascular injury, kidney diseases, and organ aging, WO, WO2025240390A1, 2025-11-20.